Financial Data and Key Metrics Changes - Total worldwide revenue in Q4 2025 was $22.6 million, a 5% decrease from $23.8 million in the same period last year, and a decrease of 7% on a constant currency basis [20] - Worldwide revenue for the full year 2025 was $90.5 million, an 8% increase over the prior year, and a 7% increase on a constant currency basis [20] - U.S. revenue in Q4 was $14.1 million, an 11% decrease from $15.9 million during the same period of the prior year [20] - International revenue in Q4 was $8.5 million, an 8% increase from $7.9 million during the same period last year [22] - Gross margin for Q4 was 77.6%, compared to 74% in the prior year [23] - Net loss for Q4 was $10.4 million or a loss of $0.25 per share, compared to a net loss of $13.2 million or a loss of $0.33 per share for the same period of the prior year [25] - Cash equivalents and marketable securities at the end of 2025 were $69.8 million, a decrease of $31.7 million from December 31, 2024 [26] Business Line Data and Key Metrics Changes - U.S. revenue for the full year 2025 was $57 million, a 1% increase over the prior year [21] - International revenue for the full year 2025 was $33.5 million, an increase of 23% over the prior year [22] - R&D expenses for Q4 were $4.6 million compared to $4 million in Q4 2024, reflecting increased clinical trial activity [24] - Sales, general, and administrative expenses for Q4 were $22.9 million compared to $27 million in Q4 2024 [24] Market Data and Key Metrics Changes - International growth was driven by continued strength in major European markets, offset by a lack of sales to the distributor in China [22] - The distributor in China is working through inventory from large orders placed in the first half of 2025, awaiting the renewal of the Chinese registration certificate expected in the second half of 2026 [22] Company Strategy and Development Direction - The company aims to re-accelerate U.S. sales growth, advance clinical initiatives, and align spending to deliver financial leverage towards profitability [7] - A focus on organizational alignment to optimize resources and decision-making in critical areas has been established [8] - The sales strategy is shifting to prioritize high-impact mandates and streamline the U.S. sales team's focus [10] - The AeriSeal program is a key focus for expanding the market, with the CONVERT II trial expected to complete enrollment in 2027 [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the underperformance in U.S. revenue was largely due to internal operational challenges and has begun implementing strategies to address these issues [7][8] - The company expects to deliver full-year 2026 revenue in the range of $90 million-$92 million, with a return to year-over-year growth anticipated in the back half of the year [26] - Management is confident in the business fundamentals and is focused on demonstrating meaningful operating leverage and reducing cash burn starting in 2026 [19][28] Other Important Information - A cost restructuring initiative has reduced ongoing operating expenses by over 10% [18] - A $60 million credit facility has been secured, extending the maturity of existing debt to 2031 and providing access to additional capital [18] Q&A Session Summary Question: What percentage of the sales force turned over in Q4? - The turnover was across the entire year, with approximately half of the sales organization experiencing turnover [31] Question: How are sales incentives structured now? - The design of the compensation plan has been adjusted to ensure it is reasonable and well-understood, with a focus on effective quota allocation [34] Question: Why wouldn't growth return sooner with the new sales force in place? - The company is starting from a position of decline, and new reps require time to ramp up productivity [41] Question: What areas contributed to the 10% cost reduction? - Most savings came from G&A and marketing, while maintaining investments in key growth areas like sales and R&D [46] Question: How will AeriSeal and the CONVERT II trial be balanced with U.S. sales investments? - The company believes that the trial's execution will not significantly impact overall spending and will be aligned with commercial operations [52] Question: What is the status of sales in China? - Sales to China are expected to resume in the back half of 2026, with minimal contributions anticipated in the first half [78]

Verastem (NasdaqCM:VSTM) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsClara Dong - VP of Equity Research in BiotechnologyDan Calkins - CFODan Paterson - President and CEOJulissa Viana - VP of Corporate Communications, Investor Relations, and Patient AdvocacyMatthew Venezia - Biotechnology Equity Research AssociateMichael Kauffman - President of DevelopmentMike Crowther - Chief Commercial OfficerYuan Zhi - Managing DirectorConference Call ParticipantsEric Schmidt - Biotechnology Analy ...

BillionToOne (NasdaqGS:BLLN) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsBrandon Couillard - Managing DirectorCasey Woodring - VP of Equity ResearchDan Arias - Managing DirectorDavid Deichler - Head of Investor RelationsDavid Westenberg - Managing Director of Equity ResearchOzan Atay - Co-founder and CEORoss Taylor - CFOConference Call ParticipantsAndrew Brackmann - Equity Research AnalystMark Massaro - Managing Director and Senior Equity Research AnalystSubbu Nambi - Managing Direc ...

American Eagle Outfitters (NYSE:AEO) Q4 2026 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsCorey Tarlowe - Senior Vice President of Equity ResearchDana Telsey - CEO and Chief Research OfficerJanet Kloppenburg - PresidentJay Sole - Managing DirectorJennifer Foyle - President and Executive DirectorJudy Meehan - Head of Investor Relations and Corporate CommunicationsMarni Shapiro - Managing PartnerMike Matthias - CFOPaul Lejuez - Managing DirectorNone - Company RepresentativeConference Call Part ...

OmniAb (NasdaqGM:OABI) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsJoseph Pantginis - Managing DirectorKurt Gustafson - EVP and CFOMatthew Foehr - President and CEOStephen D. Willey - Managing DirectorConference Call ParticipantsJacqueline Kisa - Biotechnology Specialist and AnalystMatthew Hewitt - Senior Research AnalystMichael G. King, Jr. - Managing Director and Senior Biotechnology AnalystPuneet Souda - Senior Research AnalystNone - AnalystOperatorGood afternoon, welcome to Omni ...

Niagen Bioscience (NasdaqCM:CDXC) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsAndrew Shao - SVP of Global Regulatory and Scientific AffairsJeffrey Cohen - Managing Director of Equity ResearchKendall Knysch - Senior Director of Publicity and Public RelationsOzan Pamir - CFORam Selvaraju - Managing Director of Equity ResearchRob Fried - CEOSusan Anderson - Managing DirectorConference Call ParticipantsSean McGowan - Managing Director and Senior Research AnalystOperatorLadies and gentle ...

Pulmonx (NasdaqGS:LUNG) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsAnnie Tripodo - Equity Research AssociateDerrick Sung - COO and CFOGlen French - President and CEOLaine Morgan - Head of Investor RelationsSimran Kaur - Equity Research AssociateConference Call ParticipantsJason Bednar - Managing Director and Senior Research AnalystJon Young - Director and Equity Research AnalystNelson Cox - Equity Research AnalystOperatorThank you for standing by. Welcome to the Pulmonx Q4 2025 ear ...

American Eagle Outfitters (NYSE:AEO) Q4 2026 Earnings call March 04, 2026 04:30 PM ET Company ParticipantsCorey Tarlowe - Senior Vice President of Equity ResearchDana Telsey - CEO and Chief Research OfficerJanet Kloppenburg - PresidentJay Sole - Managing DirectorJennifer Foyle - President and Executive DirectorJudy Meehan - Head of Investor Relations and Corporate CommunicationsMarni Shapiro - Managing PartnerMike Matthias - CFOPaul Lejuez - Managing DirectorNone - Company RepresentativeConference Call Part ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by an increase in milestone revenue [24] - For the full year 2025, revenue was $18.7 million compared to $26.4 million in 2024, attributed to declines in both license and milestone revenue [28] - The net loss for Q4 2025 was $14.2 million or $0.11 per share, compared to a net loss of $13.1 million or $0.12 per share in the prior year [26] - The full year net loss was $64.8 million or $0.57 per share, compared to a net loss of $62 million or $0.61 per share in 2024 [30] Business Line Data and Key Metrics Changes - The company had 107 partners running 407 active programs by year-end 2025, reflecting growth in both partner count and program activity [4][7] - There were 84 program additions in 2025, significantly higher than previous years, with a net increase of 44 programs during the year [9] - Over 98% of active programs have contracted future economics to the company, with total contracted milestone payments exceeding $3 billion [10] Market Data and Key Metrics Changes - The majority of partners are based in the U.S., with others primarily in Europe and Asia, indicating a diversified partner base [8] - Eight of the ten largest pharmaceutical companies are active partners, showcasing the strength of the company's partner relationships [8] Company Strategy and Development Direction - The company introduced OmniUltra, a transgenic chicken platform for ultra-long CDRH3s, which is expected to drive growth and attract new partners [5][20] - The xPloration platform, launched in mid-2025, is positioned for significant growth and aims to enhance partner engagement through high-throughput screening capabilities [6][22] - The company is focused on transitioning revenue from milestone-driven to more royalty-driven streams, with an average royalty rate of 3.4% across its portfolio [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong partner engagement and the potential for multiple new clinical program entries in 2026 [19][55] - The company anticipates achieving cash flow positivity as it continues to control operating costs while expanding its partner and program portfolio [32] Other Important Information - The company ended 2025 with $54 million in cash equivalents and short-term investments, with expectations to end 2026 with a cash balance of $30 million to $35 million [30] - The company implemented workforce reductions of 22 employees in 2025, contributing to lower operating expenses [29] Q&A Session Summary Question: Impact of market conditions on new program growth - Management noted strong momentum in program additions in 2025 and expressed optimism for continued growth in 2026, driven by new technologies [34][36] Question: Revenue expectations from xPloration - Management indicated that xPloration is expected to contribute significantly to revenue in 2026, with strong interest from high-tier partners [38][40] Question: Cash flow neutrality and investment strategy - Management emphasized the importance of maintaining cash flow neutrality while also investing in technologies that meet industry needs [43][47] Question: Deployment of xPloration systems - Two xPloration instruments were deployed by the end of 2025, with expectations for growth in 2026 [52] Question: Initial response to OmniUltra - The launch of OmniUltra has been well-received, with strong engagement from partners and an increase in partner programs [62][64] Question: Milestones for OmniUltra in 2026 - The focus for 2026 will be on adding partners and programs leveraging OmniUltra technology [74] Question: Royalty structures for active programs - The majority of active programs have flat royalties, with some having tiered structures [78][81]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [6][24] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million [7][26] - The company ended the year with $64.8 million in cash and no debt, reinforcing financial stability [30] Business Line Data and Key Metrics Changes - Revenue from Tru Niagen grew by 21% to $27.5 million, primarily driven by e-commerce sales of $20.2 million, which increased by 17% [26][28] - Niagen ingredient revenue was $5.6 million, up 5% year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [27] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [27] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home injection kits through a telehealth platform [10] - The market for NAD products is growing, with increased competition, particularly from NMN products [8][11] Company Strategy and Development Direction - The company aims to build on its strong foundation in NAD science, focusing on expanding its product offerings and market presence [8][10] - Plans include launching Niagen Plus branded at-home injection kits and expanding into the beauty cosmetics market [10][11] - The company is pursuing litigation against the FDA regarding NMN products, believing it has a strong case [11][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong performance in 2026 despite challenges from increased competition [8] - The company anticipates 10%-15% growth in net sales for 2026, with a slight improvement in gross margin [32][33] - Management emphasized the importance of scientific integrity and continued investment in R&D to support innovation [29] Other Important Information - The company divested its ChromaDex Reference Standards business to streamline operations and focus on core activities [13][32] - A recent patent was secured for NR and derivatives in intravenous and injectable formulations, indicating potential growth opportunities [10] Q&A Session Summary Question: Discussion on injections and SKUs - The company plans to initially offer one SKU for injections, targeting the biohacker community and expanding to other audiences later [40] Question: Guidance for the year - Management indicated that guidance is conservative, reflecting a cautious approach to revenue projections [43] Question: Growth drivers for the year - Growth is expected from existing products, new distribution channels, and increased awareness of Niagen and Tru Niagen [50] Question: Legal proceedings against the FDA - Management believes the lawsuit will not significantly impact costs and expects a summary judgment [62] Question: Share repurchase strategy - The company plans to utilize its $10 million buyback program more actively in the future [65]